Company intelligence / Profile preview

AllRock Bio

Natick, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Favorable safety and tolerability were demonstrated for ROC-101 in Phase 1 clinical trial (healthy volunteers), no associated hypotension, and target engagement of both ROCK1 and ROCK2; Phase 2a plans to assess efficacy in PAH and PH-ILD patients

Therapeutic areas: PulmonologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

ROC-101

1 more asset in the full pipeline.

Request access →

Partnerships

Drug rights for ROC-101 exclusively licensed from Sanofi

Beyond the preview

Go deeper on AllRock Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AllRock Bio.

Explore the full profile